Current Headlines

  1. Researchers Develop Faster Cancer Drug Discovery Platform
    10/2/2014

    University of Michigan researchers have developed a new method for identifying potential cancer therapeutics that speeds up the traditionally slow drug discovery process. Using this new platform, the researchers were able to identify a novel antibody which is currently being evaluated as a potential treatment for breast, ovarian, and other cancers.

  2. Compugen Discloses New Results For Novel Target Candidate For Cancer Immunotherapy
    10/1/2014

    Compugen Ltd. recently disclosed results from recent studies further confirming CGEN-15049 as a promising target candidate for cancer immunotherapy. These recent studies evaluated the function of this Compugen-discovered immune checkpoint candidate on immune cells derived from the tumor environment of melanoma patients

  3. SCRA Technology Ventures Announces SBIR Match
    9/30/2014

    SCRA Technology Ventures recently announced that Leukogene Therapeutics, Inc. (LTI) will receive a Phase I SBIR Match from its SC Launch program. LTI, a Charleston-based company, was newly accepted into the SC Launch program this month

  4. LabConnect Uses Custom Approach To Enhance Clinical Data Mining
    9/30/2014

    LabConnect, LLC., a leading provider of central laboratory services to the biopharmaceutical industry, announces the release of its BioVisualization software platform

  5. Cubist To Present New Data On Antibiotics Portfolio At IDWeek 2014
    9/30/2014

    Cubist Pharmaceuticals, Inc. recently announced that it will present new data from its antibiotics portfolio at IDWeek 2014, October 8-12, in Philadelphia, PA. Presentations of these data are important as new antibiotics are needed for the growing global public health issue of serious and sometimes life-threatening infections

  6. Scientists Develop Protein ‘Map’ For Identifying New Cancer Drugs
    9/30/2014

    Scientists at Imperial College London recently uncovered how a disease-causing enzyme can make changes to proteins, and in turn, were able to develop a protein map to identify inhibitors for the enzyme.

  7. BioLife Solutions Forms Biologistex CCM(SM) Joint Venture with SAVSU® Technologies To Market Intelligent, Controlled Temperature Containers For Biologics
    9/30/2014

    BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced the formation of a joint venture under the brand name of biologistex Cold Chain Management ("CCM"), a play on biologistics, defined as the processes, tools, and data used to monitor and manage the movement of biologic materials such as vaccines, cells, tissues, and organs across time and space

  8. Celerion Expands Ophthalmological Capabilities To Patient Populations In Collaboration With Queen's University, Belfast
    9/30/2014

    Celerion, announces the expansion of ophthalmological services in our Belfast, Northern Ireland UK facility, by building on our successful relationship with Queen’s University in Belfast

  9. Office Ally Introduces New e-Prescribing Module
    9/29/2014

    Office Ally announced recently the introduction of an e-prescribing module designed to make electronic prescribing easy and safe while enhancing patient care. In bringing this new product to market, Office Ally is partnering with Surescripts to link with over 93 percent of U.S. pharmacies

  10. MIT Team Hacks Anthrax To Deliver Cancer Drugs
    9/29/2014

    A team of chemists from the Massachusetts Institute of Technology (MIT) reported that they have turned to bacillus anthracis bacteria, the culprit behind anthrax infection, in order to deliver cancer drugs more effectively.

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.